Samsung Biologics has offered $1.8 billion in cash to acquire PolyPeptide Group, a Swiss company that specializes in manufacturing peptides. Demand for peptide medicines is growing much faster than manufacturing capacity. Drug companies need reliable manufacturers to produce these complex molecules. Note that $HIMS also owns a peptide manufacturing facility in California. It acquired the facility from C S Bio in early 2025 as part of its plan to vertically integrate its supply chain. Overall, it's another bullish signal for the long-term peptide ecosystem.
在 X 查看 ↗